Pew Scholar Charles Rice Wins Lasker-DeBakey Award for Hepatitis C Breakthrough

Innovative lab process enabled development of effective new drug therapy

Pew Scholar Charles Rice Wins Lasker-DeBakey Award for Hepatitis C Breakthrough
Hepatitis C treatment

Three scientists are being honored with the Lasker-DeBakey award for the development of a drug therapy that revolutionized the treatment of hepatitis C, a virus that attacks the liver.

© Shutterstock

Charles Rice, Ph.D., a molecular virologist at Rockefeller University and 1986 Pew biomedical scholar, received the 2016 Lasker-DeBakey Clinical Medical Research Award on Sept. 23 for his role in finding an effective treatment for hepatitis C, an infectious disease that afflicts more than 130 million people worldwide and contributes to 700,000 deaths annually. Rice devised a system to grow the hepatitis C virus in laboratory settings, allowing scientists to study its replication and ultimately invent medication that eliminates these infections in about 90 percent of patients. He shares this year’s prize with two other researchers instrumental in these discoveries: Ralf Bartenschlager, Ph.D., of Heidelberg University in Germany, and Michael Sofia, Ph.D., of Arbutus Biopharma Corp.

First recognized in 1989, hepatitis C is a bloodborne disease that often becomes chronic. No vaccine is available, and while cases vary in severity, prolonged infection can cause liver failure and cancer. The virus was notoriously difficult to study until Rice’s breakthrough in the mid-1990s. He identified a piece of its RNA sequence that had eluded other researchers and is key to its reproduction.

Based on this discovery, Rice and Bartenschlager engineered an efficient way to replicate the virus in lab-grown host cells, making it possible to observe its entire life cycle and develop tests to screen for infections. Sofia and his team built on this foundational research in their successful quest for a compound that would block the virus’ machinery for making copies of itself. Their resulting drug therapy was approved by the U.S. Food and Drug Administration in 2013 to treat patients with chronic hepatitis C infection.

Rice was part of the second annual class of the Pew Scholars Program in the Biomedical Sciences and is the fifth alumnus to be honored with the prestigious Lasker Award, joining previous winners Stephen Elledge, Richard Scheller, Carol Greider, and Roderick MacKinnon. The advances in scientific knowledge and human health that earned these scholars this distinction are a testament to the importance of investing in promising researchers early in their careers.

Kara Coleman directs Pew’s biomedical research programs.

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Ancient evolutionary DNA can help fight modern viruses
Ancient evolutionary DNA can help fight modern viruses
Article

Viral DNA May Help Human Body Fight Infections

Pew scholar unlocks immune system trait that is possible key to survival

Quick View
Article

In the March issue of Science magazine, 2012 Pew scholar Nels Elde, Ph.D., and his colleagues unveiled research that illustrates one of the most elegant characteristics of human evolution: Our bodies are remarkably adaptable and programmed to take in that which could harm us and repurpose it for our benefit.

Lab
Lab
Article

In Step With Pew’s Programs in the Biomedical Sciences

A chat with project director Kara Coleman

Quick View
Article

In June, the Pew Programs in the Biomedical Sciences will announce its 2016 class of Pew biomedical scholars, Latin American fellows, and Pew-Stewart Scholars for Cancer Research. We interviewed project director Kara Coleman about the programs’ work supporting early-career scientists.